https://www.facebook.com/105642562120922/

OPTOMETRISTS, 720 n cahuenga Boulevard, Los Angeles, CA (2026)

09/06/2026

STEREOGRAM CHALLENGE

Stereograms are designed to create the illusion of depth by presenting repeating patterns that can reveal a hidden 3D image when viewed correctly.

Instructions:

• Hold your phone at a comfortable reading distance.

• Relax your eyes and look “through” the image rather than directly at the pattern.

• Allow the hidden image to gradually come into focus.

• If you don’t see it immediately, try moving the phone slightly closer or farther away.

🔍 How many bars can you see?

Comment your answer below:

1️⃣ 2️⃣ 3️⃣ 4️⃣ 5️⃣

The number of bars you see depends on the depth your visual system is able to perceive within the stereogram.

Challenge your friends and compare your results!

Subscribe to our YouTube channel:
Optometrists2024 YouTube Channel⁠

09/06/2026

Pediatric Myopia: Digital Defocus VR Headset Shows Potential to Slow Eye Elongation

Could a 15 minute daily virtual reality session become a new tool for controlling childhood myopia?

A newly published randomized clinical trial in JAMA Ophthalmology evaluated a virtual reality based Digital Defocus Vision Training (DDVT) system designed to deliver controlled visual defocus. The results suggest that this approach may modestly reduce axial eye growth and myopic progression over six months. However, the researchers emphasize that longer term clinical significance remains uncertain.

1️⃣ Why is eye elongation important in myopia?

Myopia is not simply about blurred distance vision.

In many children, progressive myopia is associated with axial elongation, meaning the eye gradually becomes longer from the cornea toward the retina.

Continued excessive axial growth can increase the lifetime risk of complications associated with high myopia, including myopic macular degeneration, retinal detachment and other structural changes.

This is why modern myopia management increasingly focuses on slowing axial elongation, rather than simply correcting the refractive error.

2️⃣ What is Digital Defocus Vision Training?

The technology uses a head mounted virtual reality device to provide controlled visual stimuli designed to create a defocus signal.

The concept is related to the growing understanding that the peripheral retina can contribute to signals involved in regulating ocular growth.

Instead of relying solely on conventional optical lenses, DDVT attempts to deliver a carefully designed digital visual environment that may influence the biological signals associated with eye growth.

3️⃣ What did the clinical trial involve?

The randomized clinical trial was conducted at a single center in Guangzhou, China, and included 120 children aged 6 to 12 years with myopia.

The children were randomly assigned to two groups:

🔹 DDVT plus single vision spectacles
🔹 Single vision spectacles alone

Children in the DDVT group used the VR headset for 15 minutes every day at home, under parental supervision, following an initial training session at the hospital.

The researchers followed the participants for six months. Of the 120 randomized children, 116 completed the study.

4️⃣ What happened to axial length?

This was the study’s primary outcome.

After six months:

DDVT group: axial length increased by 0.15 mm

Control group: axial length increased by 0.25 mm

That represents a between group difference of approximately 0.11 mm, favoring the VR based intervention.

The difference was statistically significant, with P < .001.

5️⃣ What about refractive progression?

The researchers also measured spherical equivalent refraction.

The DDVT group changed by approximately:

−0.23 D

compared with:

−0.46 D

in the single vision spectacle group.

The between group difference was approximately 0.23 D, again favoring the DDVT group.

In other words, children using the digital defocus system experienced less myopic refractive progression during the six month study period.

6️⃣ Was the treatment safe?

Importantly, no training related adverse events were reported during the trial.

The home based nature of the intervention is also interesting. A short daily session could potentially make digital myopia management easier to integrate into children’s routines if future studies confirm sustained benefits.

However, safety over six months does not establish long term safety or effectiveness.

🧠 Key Clinical Concept

The most interesting aspect of this research is not simply the use of VR.

It is the attempt to use digital visual stimulation as a biological signal for regulating ocular growth.

Traditional myopia control approaches include specialized spectacle lenses, contact lenses, orthokeratology and pharmacological treatment. DDVT represents a different direction by attempting to manipulate the visual environment digitally.

The study therefore raises an intriguing question:

Can carefully engineered visual experiences become another tool for controlling childhood eye growth?

⚠️ But is VR now a proven myopia treatment?

Not yet.

Although the trial produced statistically significant differences, the absolute reduction in axial elongation was relatively small and the follow up period was only six months.

The JAMA authors specifically state that the clinical relevance of these differences over the short and long term cannot yet be determined. They describe DDVT as a promising adjunctive approach that requires additional investigation.

This is particularly important because myopia is a long term condition. A meaningful myopia control strategy needs to demonstrate that its effect can be maintained over several years, not simply over a few months.

👓 For Eye Care Professionals

This technology could eventually become an interesting addition to the expanding field of digital therapeutics for myopia management.

But at present, clinicians should view VR based DDVT as an emerging investigational approach, not as a replacement for established myopia management strategies.

Future research needs to determine:

🔹 Whether the reduction in axial elongation persists beyond six months
🔹 Whether the effect increases or diminishes with longer treatment
🔹 How DDVT compares directly with established myopia control methods
🔹 Which children are most likely to benefit
🔹 Whether adherence remains high over several years
🔹 Whether long term use produces clinically meaningful reductions in high myopia and its complications

🔬 The Bigger Picture

Myopia management is rapidly moving beyond simply prescribing stronger glasses.

From optical defocus and pharmacological approaches to digital visual therapy, researchers are exploring multiple ways to influence the biological mechanisms responsible for excessive eye growth.

This VR study provides an early clinical signal that digital defocus may have a role in future pediatric myopia management.

But for now, the most accurate conclusion is:

Promising technology. Encouraging six month results. More evidence is needed before VR based defocus becomes routine myopia control.

Subscribe to our youtube channel at:
https://youtube.com/?si=2QfmCdErirozLqMg

📚 Sources

JAMA Ophthalmology
“Digital Defocus Vision Training Using Virtual Reality for Myopia Control: A Randomized Clinical Trial”
https://jamanetwork.com/journals/jamaophthalmology/article-abstract/2853325

ClinicalTrials.gov
NCT07042022
https://clinicaltrials.gov/study/NCT07042022

09/06/2026

Posterior fibrovascular membrane of the lens
This fibrous stalk has pretty much degenerated completely, which is what we’d expect to see with posterior persistent fetal vasculature (PFV) residue.

09/06/2026

——————TIMOLOL—————

T - Tear production
I - IOP lowering (mechanism)
M - Masked hypoglycemia
O - Obstructive airway exacerbation
L-Lethargy/ depression
0 - Ocular surface disease
L-Low heart rate (bradycardia)

09/06/2026

A billionaire luxury collection part-II for the eye-care.❤️

If you’re billionaire, would you have these ? 😁😍

We created this luxury collection as a tribute to the professionals who dedicate their lives to protecting vision and advancing eye care. 💛

If these instruments were displayed in a luxury eye-care museum, which one would you choose to own or showcase? 👇

❤️ Share this with an Optometrist, Ophthalmologist, Vision Scientist, or Eye-Care Professional who would appreciate the artistry behind these creations.

🔁 Let’s see how far this reaches. Every share helps celebrate the profession we love.(10k shares)

Comment INTERESTED if you’d like to see Part III featuring more luxury ophthalmic instruments, advanced diagnostic devices, and futuristic eye-care technology.

Support us on youtube at:
https://youtube.com/?si=_KXJ7OlKj1aKBiQ4

Follow our IG account OPTOMETRISTS for more.

09/05/2026

Glaucoma Breakthrough: KAIST Linked Smart Contact Lens Enables Continuous Eye Pressure Monitoring

What if a contact lens could do more than correct vision?

Imagine wearing a transparent lens that can continuously monitor changes in the eye and wirelessly transmit physiological information without interfering with normal vision.

That concept is becoming increasingly realistic as researchers develop smart contact lenses for glaucoma monitoring, combining flexible sensors, wireless electronics and advanced nanomaterials into an extremely thin wearable platform.

Researchers involving KAIST, South Korea, contributed to the development of a soft and transparent smart contact lens capable of quantitatively monitoring intraocular pressure (IOP) in real time. The device was tested in animal models and in human participants, demonstrating the potential for continuous, noninvasive glaucoma monitoring.

1. Why continuous IOP monitoring matters

In glaucoma, elevated or fluctuating IOP can contribute to progressive optic nerve damage.

The problem is that conventional tonometry provides only a snapshot measurement.

IOP changes throughout the day and can vary with:

👁️ Body position
👁️ Physical activity
👁️ Circadian rhythm
👁️ Medication effects
👁️ Episodic pressure fluctuations

A patient can therefore have a normal IOP during a clinic visit while experiencing clinically important pressure fluctuations at other times.

A wearable sensor that continuously records IOP could potentially provide a much more complete picture of an individual’s pressure profile.

2. How does a smart contact lens work?

The concept is surprisingly elegant.

When IOP changes, the shape and mechanical strain of the ocular surface can change slightly.

A sensor incorporated into the contact lens can detect these mechanical changes and convert them into an electrical signal.

The KAIST linked system incorporated:

🔹 A flexible strain sensor
🔹 Wireless communication components
🔹 Capacitors and resistors
🔹 Stretchable electrical interconnections
🔹 An integrated circuit

The information could then be transmitted wirelessly and analyzed using a smartphone or external receiver.

The result is essentially a wearable ocular pressure monitor that sits directly on the eye.

3. What makes the technology different?

Traditional tonometry requires a patient to visit a clinic.

A smart contact lens could potentially collect information while the patient goes about normal daily activities.

That means researchers can investigate pressure patterns that may otherwise remain invisible during a short clinical examination.

Earlier smart lens research has already demonstrated the feasibility of 24 hour IOP monitoring, including measurements during sleep, using soft contact lens platforms.

This opens the possibility of moving glaucoma monitoring from occasional measurements toward continuous personalized monitoring.

4. What about the human testing?

One of the important aspects of the KAIST linked research is that the technology was not limited to a laboratory demonstration.

The lens was evaluated in rabbits, where its measurements corresponded with those obtained using a commercial tonometer.

The researchers then evaluated the device in 10 human participants.

The lens was reported to be safe and capable of providing quantitative IOP measurements without inducing ocular inflammation during the study.

That human testing is an important step because smart contact lenses must satisfy much more than sensor sensitivity.

They must also be:

👁️ Comfortable
👁️ Transparent
👁️ Mechanically flexible
👁️ Biocompatible
👁️ Stable on the ocular surface
👁️ Accurate during normal eye movement

5. Where do graphene and carbon nanotubes fit in?

Graphene and carbon nanotubes are particularly attractive materials for smart contact lenses because they combine electrical conductivity, mechanical flexibility and potential optical transparency.

Research has demonstrated graphene and carbon nanotube based sensing layers capable of detecting mechanical changes associated with IOP.

For example, a graphene and carbon nanotube pressure sensor embedded in a soft contact lens demonstrated continuous pressure tracking across a physiologic IOP range in an experimental eye model.

More recent research is also exploring graphene based sensors, reduced graphene oxide composites and other nanomaterials to improve sensitivity and miniaturization.

These technologies could eventually allow the sensing circuitry to become increasingly thin and transparent.

6. What does “self powered” mean?

One of the biggest engineering challenges for smart contact lenses is power.

A conventional battery is bulky and unsuitable for direct placement on the cornea.

Researchers have therefore investigated several alternative approaches, including:

🔋 Micro batteries
⚡ Wireless power transfer
☀️ Organic solar cells
🧬 Tear based biofuel cells
🔬 Energy harvesting systems

A separate research group has demonstrated self powered smart contact lenses using glucose fuel cells, generating electrical power from glucose and oxygen while maintaining flexibility and durability.

This is an important distinction:

Self powered smart lenses and KAIST’s IOP monitoring lens represent related technological directions, but they are not necessarily the same device.

The broader field is moving toward lenses that can integrate sensing, power generation and wireless communication into a single platform.

7. Could this actually change glaucoma care?

Potentially, yes.

Imagine a patient wearing a smart lens during normal daily activities.

Instead of receiving one IOP measurement during a clinic appointment, the clinician could eventually have access to a much larger pressure profile.

That could help researchers investigate:

📈 Pressure peaks
🌙 Nighttime IOP behavior
💊 Response to glaucoma medication
🏃 Pressure changes during activity
⏰ Circadian fluctuations
👁️ Individual pressure patterns

In the future, such information could potentially contribute to more personalized glaucoma management.

However, continuous measurement does not automatically mean better clinical outcomes.

Large clinical studies would still be required to demonstrate whether smart lens based monitoring improves diagnosis, treatment decisions or long term visual outcomes.

8. Smart lenses could eventually become more than pressure monitors

The technology is not limited to IOP.

Researchers are developing smart contact lenses capable of sensing or interacting with different biological signals.

Potential applications include:

🧪 Tear glucose monitoring
👁️ IOP monitoring
🔬 Inflammatory biomarker detection
💊 Controlled drug delivery
📡 Wireless physiological monitoring
🧠 Eye movement and neurological signal detection

Some experimental systems have even combined IOP sensing with on demand glaucoma drug delivery, creating a theranostic contact lens capable of both monitoring pressure and responding to elevated IOP in animal models.

This points toward a future in which a contact lens could potentially become a miniature diagnostic and therapeutic platform.

🔬 Key Clinical Concept

A smart contact lens is not simply a contact lens with a sensor added to it.

It represents a miniature wearable medical platform integrating:

Sensor + flexible electronics + power + wireless communication + ocular compatibility

The ultimate goal is to obtain clinically useful physiological information continuously while maintaining the comfort and optical properties expected from a conventional contact lens.

👨‍⚕️ For Eye Care Professionals

For optometrists and ophthalmologists, this technology could eventually provide information that conventional office based tonometry cannot capture.

But there are still major challenges.

Long term ocular safety must be demonstrated.

Sensor calibration must remain reliable during blinking, eye movement, tear film changes and varying corneal geometry.

The technology must also demonstrate that measurements are sufficiently accurate and reproducible for clinical decision making.

Most importantly, researchers need evidence showing that continuous monitoring actually improves glaucoma diagnosis, treatment optimization or prevention of visual field loss.

At present, smart contact lenses remain an emerging technology rather than a replacement for established glaucoma diagnostics.

👁️ Bottom Line

The idea is remarkable:

A transparent contact lens could potentially become a continuous wearable monitor for the eye.

KAIST linked research demonstrated that a soft, transparent lens could quantitatively monitor IOP and perform safely in an initial human study.

Meanwhile, advances in graphene, carbon nanotubes, self powered systems and wireless electronics are pushing smart contact lenses toward increasingly sophisticated capabilities.

The long term vision is even more ambitious:

A contact lens that can sense the eye, communicate the information wirelessly and potentially respond to disease in real time.

For glaucoma care, that could eventually mean moving from occasional pressure measurements toward continuous, personalized monitoring of the eye.

Subscribe to our youtube channel:

https://youtube.com/?si=OdR8gOQupb9YyPih

📚 Sources

Nature Biomedical Engineering — A Soft and Transparent Contact Lens for the Wireless Quantitative Monitoring of Intraocular Pressure
https://www.nature.com/articles/s41551-021-00719-8

PubMed — A Soft and Transparent Contact Lens for the Wireless Quantitative Monitoring of Intraocular Pressure
https://pubmed.ncbi.nlm.nih.gov/33941897/

KAIST Research Portal — Smart Contact Lens Research
https://pure.kaist.ac.kr/en/publications/a-soft-and-transparent-contact-lens-for-the-wireless-quantitative/

Nature Communications — Smart Soft Contact Lenses for Continuous 24 Hour Monitoring of Intraocular Pressure in Glaucoma Care
https://www.nature.com/articles/s41467-022-33254-4

Nature Communications — Intelligent Wireless Theranostic Contact Lens for Electrical Sensing and Regulation of Intraocular Pressure
https://www.nature.com/articles/s41467-022-29860-x

ACS Nano — Safe, Durable, and Sustainable Self Powered Smart Contact Lenses
https://pubs.acs.org/doi/10.1021/acsnano.2c05452

Nanotechnology — A Wearable Contact Lens Sensor for Noninvasive In Situ Monitoring of Intraocular Pressure
https://pubmed.ncbi.nlm.nih.gov/33290267/

09/05/2026

Corneal Blindness: iPSC Stem Cell Sheets Could Help Rebuild a Damaged Corneal Surface

Imagine treating severe corneal surface damage not simply by replacing tissue, but by rebuilding the corneal epithelium using living cells created from stem cells.

That possibility is moving from laboratory research into human clinical studies.

Researchers at Osaka University, Japan reported the first human transplantation of induced pluripotent stem cell derived corneal epithelial cell sheets in patients with severe limbal stem cell deficiency (LSCD). The early findings provide an important proof of concept for regenerative treatment of the ocular surface.

1. Why is the limbus so important?

The limbus is the junction between the cornea and conjunctiva and contains stem cells responsible for maintaining and renewing the corneal epithelium.

When these cells are severely damaged or depleted, the corneal surface can no longer regenerate normally.

This can lead to:

👁️ Persistent corneal epithelial defects
👁️ Corneal vascularization
👁️ Corneal opacity
👁️ Irregular ocular surface
👁️ Severe discomfort
👁️ Reduced visual acuity and visual impairment

This condition is known as limbal stem cell deficiency.

2. What are iPSC derived corneal epithelial sheets?

Induced pluripotent stem cells, or iPSCs, are adult cells that have been reprogrammed into a stem cell state.

Researchers can then direct these cells toward specific cell types.

In this approach, iPSCs are differentiated into corneal epithelial cells and organized into a thin transplantable structure called an iPSC derived corneal epithelial cell sheet, or iCEPS.

The sheets contain approximately three to five layers of cells and demonstrate characteristics of normal corneal epithelium. Laboratory testing showed expression of markers including p63, keratin 12, keratin 3 and mucin 16.

The goal is not simply to place a biological covering over the cornea.

The objective is to reconstruct a living corneal epithelial surface.

3. The first human transplantation

The landmark first in human study involved four eyes of four patients with LSCD.

All four received allogeneic human iPSC derived corneal epithelial cell sheets after removal of abnormal conjunctival tissue from the affected ocular surface.

The study was nonrandomized and single arm, with safety as the primary outcome and efficacy assessed as a secondary outcome.

The results were encouraging.

At 52 weeks:

🔹 LSCD severity improved in the treated eyes
🔹 Corrected distance visual acuity improved in all four patients
🔹 Corneal opacity improved in all four patients
🔹 The corneal surface became more stable
🔹 Improvements in ocular surface findings were maintained during follow up

For some patients, the improvement in LSCD stage was substantial. Two patients improved from Stage III to Stage IA, while another improved from Stage IIB to Stage IA.

Importantly, the study shows that the approach could produce both anatomical improvement and functional visual improvement.

4. What about rejection and tumor formation?

This is one of the most important safety questions when working with pluripotent stem cells.

Because iPSCs have the potential for abnormal cellular growth, researchers must carefully monitor for tumorigenesis and other unwanted tissue formation.

During the reported follow up, there were no cases of clinical rejection or tumorigenesis reported in the treated eyes.

However, this finding must be interpreted carefully.

Only four patients were treated in the first human study.

A small study cannot establish the long term safety of a regenerative therapy for the wider population.

That is why larger clinical trials are essential.

5. The technology has now moved into Phase 2

The next important step is the REM 01 Phase 2 clinical trial.

The Japanese registry lists REM 01 as a single arm, open label study investigating an allogeneic iPSC derived corneal epithelial cell sheet in patients with limbal stem cell deficiency. The study is currently listed as recruiting and plans to enroll 12 participants.

The trial includes patients aged 16 years or older with Stage IIB, IIC or III LSCD.

The primary outcome is:

Successful corneal epithelial reconstruction at 52 weeks after transplantation.

Researchers will also evaluate:

👁️ LSCD severity
👁️ Corrected visual acuity
👁️ Corneal opacity
👁️ Corneal neovascularization
👁️ Symblepharon
👁️ Corneal epithelial defects
👁️ Rejection
👁️ Neoplastic lesions
👁️ Other adverse events

The registry identifies REM 01 as an unapproved regenerative medicine product under investigation.

6. Why could this be important?

Current treatments for severe LSCD can involve transplantation or cultivation of limbal epithelial tissue and other complex ocular surface reconstruction procedures.

An iPSC based approach could potentially provide a standardized and scalable source of corneal epithelial tissue.

This creates a fascinating regenerative pathway:

🧬 iPSCs
⬇️
🔬 Corneal epithelial differentiation
⬇️
🧫 Engineered cell sheet
⬇️
👁️ Transplantation
⬇️
🌱 Ocular surface reconstruction

If larger studies confirm the early findings, this technology could eventually expand the treatment options available for patients with severe ocular surface failure.

7. Is this a cure for corneal blindness?

No, not yet.

This distinction is extremely important.

The first human study specifically targeted limbal stem cell deficiency, rather than every cause of corneal blindness.

Corneal vision loss can also result from stromal scarring, endothelial disease, keratoconus, infection, trauma and many other conditions.

An epithelial cell sheet would not necessarily correct all of these problems.

Therefore, the most accurate description is:

An investigational regenerative strategy for severe limbal stem cell deficiency.

It should not currently be described as a universal cure for corneal blindness.

🔬 Key Clinical Concept

The exciting part of this technology is that researchers are attempting to rebuild the living corneal epithelium, rather than simply replacing damaged tissue with a passive covering.

The first human study provided encouraging evidence of ocular surface and visual improvement, but the evidence is still based on a very small number of patients.

The ongoing Phase 2 REM 01 study is therefore an important step toward determining whether these findings can be reproduced safely and consistently in a larger patient population.

👨‍⚕️ For Eye Care Professionals

This emerging technology brings together:

🧬 Stem cell biology
👁️ Corneal epithelial regeneration
🔬 Tissue engineering
🏥 Ocular surface surgery
🧪 Regenerative medicine

For optometrists and ophthalmologists, the important message is not that iPSC therapy has already replaced conventional corneal transplantation.

Rather, the ocular surface may be entering an era in which living, engineered epithelial tissue can be produced and transplanted to restore damaged corneal surfaces.

The major questions now are durability, reproducibility, long term safety, immune response and whether epithelial reconstruction can provide sustained functional visual improvement.

👁️ Bottom Line

The concept is remarkable:

Instead of simply replacing a damaged corneal surface, researchers are attempting to rebuild it using living cells derived from iPSCs.

The first human study involving four eyes showed encouraging improvements in LSCD, visual acuity and corneal opacity.

Now, the Phase 2 REM 01 trial is taking this approach into a larger clinical investigation, with corneal epithelial reconstruction as its primary endpoint.

The future of corneal regeneration may not only involve donor tissue. It may also involve engineered living tissue created from stem cells.

📚 Sources

The Lancet
https://pubmed.ncbi.nlm.nih.gov/39522528/

PMC / Full Text of The Lancet Study
https://pmc.ncbi.nlm.nih.gov/articles/PMC11694011/

Japan Registry of Clinical Trials — REM 01 Phase 2
https://jrct.mhlw.go.jp/en-latest-detail/jRCT2053260029

Japan Registry of Clinical Trials — Japanese Record
https://jrct.mhlw.go.jp/latest-detail/jRCT2053260029

The Lancet — Commentary on iPSC Corneal Regeneration
https://pubmed.ncbi.nlm.nih.gov/39522525/

09/05/2026

Without googling it, enlist the possible causes of sudden vision loss!!!

09/05/2026

Advanced Proliferative Diabetic Retinopathy (PDR) management with tractional retinal detachment (TRD) often requires meticulous segmentation and delamination of fibrovascular membranes. When utilizing a unimanual scissors technique (typically vertical, curved, or horizontal micro-scissors), the surgeon operates without the luxury of a secondary bimanual grasping instrument, requiring strategic use of the cutter, tissue properties, and viscoelastic interfaces.Here is a clinical and technical overview of performing unimanual segmentation and delamination.
📸: Dr Ahmed Mohamed Fath Elbab

09/05/2026

Best Disease — the classic “egg-yolk” stage on fundus autofluorescence

This striking hyperautofluorescent vitelliform lesion represents the classic “egg-yolk” stage of Best vitelliform macular dystrophy (BVMD).

Best disease is most commonly an autosomal dominant macular dystrophy caused by pathogenic variants in BEST1, which encodes bestrophin-1, a Ca²⁺-activated anion channel predominantly located on the basolateral membrane of retinal pigment epithelium (RPE) cells.

Bestrophin-1 dysfunction alters ionic and fluid homeostasis at the RPE–photoreceptor interface and is associated with impaired handling and degradation of shed photoreceptor outer segments. Normally, the RPE continuously phagocytoses these outer segments as part of photoreceptor renewal. Bisretinoid fluorophores derived from the visual cycle and photoreceptor outer segments are subsequently processed within RPE lysosomes.

In Best disease, abnormal RPE function and impaired outer-segment processing contribute to the accumulation of vitelliform material containing lipofuscin/bisretinoid fluorophores, together with subretinal material and fluid. Because these fluorophores strongly emit light when excited during fundus autofluorescence imaging, the intact vitelliform lesion appears intensely hyperautofluorescent.

🔑 Teaching point: the “egg yolk” is not simply a deposit of lipofuscin produced by the RPE. It reflects disease of the photoreceptor–RPE interface, in which BEST1 dysfunction disrupts ion/fluid transport and outer-segment handling, leading to accumulation of autofluorescent material at and around the RPE–photoreceptor interface.

BEST1 mutation → RPE ion/fluid dysfunction → impaired photoreceptor outer-segment handling → accumulation of bisretinoid/lipofuscin-rich vitelliform material → intense hyperautofluorescence.

OPTOMETRISTS

09/06/2026

09/06/2026

09/06/2026

09/06/2026

09/06/2026

09/05/2026

09/05/2026

09/05/2026

09/05/2026

09/05/2026

Address

Website

Alerts

Shortcuts

Sponsored

Share

Category

Listing takedown request